481TiP Checkmate 722: A phase 3 trial of nivolumab with chemotherapy or ipilimumab vs chemotherapy in epidermal growth factor receptor (EGFR)-mutation, T790M-negative stage IV or recurrent non-small cell lung cancer (NSCLC) after EGFR tyrosine kinase inhibitor (TKI) therapy
| Autor: | Y-L. Wu, Kazuhiko Nakagawa, I.-F. Chang, A. Blackwood-Chirchir, Justin F. Gainor, Y. Ohe, Keunchil Park, J.C.-H. Yang, R. Yang, Tony Mok |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Oncology
medicine.medical_specialty medicine.medical_treatment Ipilimumab 01 natural sciences T790M 010104 statistics & probability 03 medical and health sciences 0302 clinical medicine Recurrent Non-Small Cell Lung Cancer Internal medicine Medicine Epidermal growth factor receptor 0101 mathematics Chemotherapy biology business.industry Hematology 030220 oncology & carcinogenesis biology.protein Nivolumab business Stage iv Egfr tyrosine kinase medicine.drug |
| Zdroj: | Annals of Oncology. 27 |
| ISSN: | 1569-8041 0923-7534 |
| DOI: | 10.1093/annonc/mdw594.045 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|